 Home > Medical News > Latest Medical News > Danaher Life Sciences and WuXi Biologics jointly launch industry initiatives and release biopharmaceutical solutions

Danaher Life Sciences and WuXi Biologics jointly launch industry initiatives and release biopharmaceutical solutions

 Last Update: 2021-08-09
 Source: Internet
 Author: User

Tags

multi advantage dogs

drugs system surgery

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A few days ago, the Biopharmaceutical Ecosystem Innovation and Cooperation Summit jointly organized by Danaher Life Sciences and WuXi Biologics, with the China Biochemical and Pharmaceutical Industry Association as the guiding unit, was grandly held at the Jumeirah Himalayas Hotel in Shanghai

Big coffee gathered, stars shining

On the afternoon of the first day, Danaher Life Sciences New Product Launch Conference and WuXi Biologics Integrated Technology Empowerment Platform Promotion Conference kicked off first

Danaher Life Sciences and WuXi Biologics agree that: to form an ecosystem that is conducive to the healthy development of the biopharmaceutical industry, it is necessary to reach a broad consensus in the industry to form basic scientific research, product research and development, to commercial production, and government The relevant supervision of the company cooperates with each other and jointly promotes a good situation of healthy development

Mr.

In the media Q&A session, President Li Bing gave an in-depth answer to Danaher Life Sciences' localization plan and its role in the ecosystem

In the ecosystem, Danaher Life Sciences can provide a series of products from target discovery, antigen preparation to antibody production in the research and development of biological drugs; in production, it provides process solutions from upstream, downstream to preparation canning; in In terms of ensuring drug safety and effective quality control, it can provide a complete testing program from form, structure, function to residue

Mr.

Dr.

After the press conference, Danaher Life Sciences released a biopharmaceutical solution.

With a collection of boutiques and new products, Danaher Life Sciences’ biopharmaceutical solutions also grandly launched four high-tech new products and one solution in 2021.

The climax appeared at the VIP dinner.

Release Ceremony of Biopharmaceutical Industry Initiative Declaration

The proposal is not just a slogan, but an attitude, and it needs to be practiced.

The issuance of the industry initiative declaration has aroused widespread recognition among practitioners in the biopharmaceutical field

About Danaher Life Sciences

Danaher is an innovator in the field of global life science services.

Danaher Life Sciences China was established on June 1, 2019, aiming to take root in the Chinese market and provide Chinese users with better products and services

Currently, the platform companies include Integrated DNA Technologies Inc.
Edtec Biotechnology Co.
, Ltd.
, Beckman Coulter Trading (China) Co.
, Ltd.
, Megol Molecular Instruments (Shanghai) Co.
, Ltd.
, Shanghai Aibocaisi Analytical Instruments Trading Co.
, Ltd.
, Tianjin Bo Nayijieer Technology Co.
, Ltd.
, Leica Microsystems (Shanghai) trading Co.
, Ltd.
and Pall (China) Co.
, Ltd
.

About WuXi Biologics

WuXi Biologics (stock code: 2269.
HK), as a Hong Kong listed company, is the world's leading open and integrated biopharmaceutical capabilities and technology empowerment platform
.
The company provides a full range of end-to-end R&D services for global biopharmaceutical companies and biotechnology companies to help anyone and any company discover, develop and produce biopharmaceuticals, realize the whole process from concept to commercial production, and accelerate global biopharmaceutical research and development Process, reduce research and development costs, and benefit patients
.

As of March 22, 2021, 361 comprehensive projects have been developed on WuXi Biologics platform, including 190 in preclinical research phase, 137 in early clinical phase (phase I, phase II), and 32 in late clinical phase (Phase III) and 2 are in the commercial production stage
.
It is estimated that by 2024, the company's planned biopharmaceutical production bases in China, Ireland, the United States, Germany and Singapore will have a combined production capacity of 430,000 liters, which will effectively ensure that the company provides customers with global quality through a sound and strong global supply chain network.
Standard biological medicine
.

WuXi Biologics regards Environment, Society and Governance (ESG) as an important part of business development and corporate spirit, and has established an ESG committee led by the CEO to implement sustainability commitments while improving operational efficiency
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.